Differential effect of prior β-lactams and fluoroquinolones on risk of bloodstream infections secondary to Pseudomonas aeruginosa

Diagn Microbiol Infect Dis. 2017 Jan;87(1):87-91. doi: 10.1016/j.diagmicrobio.2016.09.017. Epub 2016 Sep 24.

Abstract

Objective: This retrospective case-control study examines risk factors for bloodstream infections (BSI) due to Pseudomonas aeruginosa (PSA).

Methods: Hospitalized adults with Gram-negative BSI at Palmetto Health from 2010 to 2015 were identified. Multivariate logistic regression was used to examine PSA BSI risk factors.

Results: Seventy and 910 patients with PSA and Enterobacteriaceae BSI, respectively, were included. Prior use of β-lactams (adjusted odds ratio [aOR] 3.9, 95% confidence intervals [CI]: 2.3-6.9), but not fluoroquinolones (aOR 1.0, 95% CI: 0.4-2.2), was a risk factor for PSA BSI. Immune compromised status (aOR 3.7, 95% CI: 2.0-6.7), respiratory source (aOR 4.4, 95% CI: 2.1-8.9), and prolonged hospitalization (aOR 1.9, 95% CI: 1.1-3.5), were predictors of PSA BSI.

Conclusions: Determination of class of previously used antibiotics among other clinical variables helps identify patients at risk of PSA BSI and offers opportunities to optimize empirical antimicrobial therapy.

Keywords: Antibiotic resistance; Antimicrobial agents; Bacteremia; Pseudomonas aeruginosa; Sepsis.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteremia / epidemiology*
  • Case-Control Studies
  • Enterobacteriaceae / isolation & purification
  • Enterobacteriaceae Infections / epidemiology
  • Female
  • Fluoroquinolones / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Pseudomonas Infections / epidemiology*
  • Pseudomonas aeruginosa / isolation & purification*
  • Risk Assessment
  • beta-Lactams / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • Fluoroquinolones
  • beta-Lactams